3-(哌啶-1-羰基)苯基硼酸 | 850568-34-2

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(哌啶-1-羰基)苯基硼酸
• 中文别名: 3-(1-哌啶羰基)苯硼酸
• 英文名称: (3-(piperidine-1-carbonyl)phenyl)boronic acid
• 英文别名: [3-(1-piperidinylcarbonyl)phenyl]boronic acid；3-(Piperidine-1-carbonyl)phenylboronic acid；[3-(piperidine-1-carbonyl)phenyl]boronic acid
• CAS: 850568-34-2
• 化学式: C₁₂H₁₆BNO₃
• mdl: MFCD04115686
• 分子量: 233.075
• InChiKey: XFTARKGZGNWJJT-UHFFFAOYSA-N

物化性质

• 熔点：
  150-154°C
• 沸点：
  469.8±47.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.51
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  60.8
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090
• 危险性防范说明：
  P264,P271,P302+P352,P305+P351+P338,P362,P403+P233,P501
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
3-(Piperidine-1-carbonyl)phenylboronic acid
Product Name:
Synonyms: 1-(3-Boronobenzoyl)piperidine; (3-boronophenyl)(piperidin-1-yl)methanone

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
3-(Piperidine-1-carbonyl)phenylboronic acid
Ingredient name:
CAS number: 850568-34-2

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C12H16BNO3
Molecular weight: 233.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(哌啶-1-羰基)苯基硼酸 、 4,7-二溴-1H-吲哚 在 bis-triphenylphosphine-palladium(II) chloride 、 caesium carbonate 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以46%的产率得到(3-{7-[3-(piperidine-1-carbonyl)-phenyl]-1H-indol-4-yl}-phenyl)-piperidin-1-yl-methanone
  参考文献：
  名称：

  4,7-Diaryl indole-based fluorescent chemosensor for iodide ions

  摘要：

  Simple and selective indole based fluorescent sensors for iodide anions are reported. A series of 4,7-diaryl indole derivatives (DAIs) are designed and synthesized using Suzuki coupling. These DAIs shows significant changes in UV-vis and fluorescent intensity only with addition of iodides and not with other anions. The ability of these DAIS to function as selective iodide chemosensor is reported. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2011.04.039

文献信息

• MORPHOLINYL AND PYRROLIDINYL ANALOGS
  申请人：Goodman Krista B.

  公开号：US20080021023A1

  公开（公告）日：2008-01-24

  The present invention relates to morpholinyl, and pyrrolidinyl analogs, pharmaceutical compositions containing them, and their use as antagonists of urotensin II.

  本发明涉及吗吗啉基和吡咯啉基类似物，含有它们的药物组合物，以及它们作为尿苷II拮抗剂的用途。
• Discovery of Arylsulfonamides as Dual Orexin Receptor Agonists
  作者：Dehui Zhang、David A. Perrey、Ann M. Decker、Tiffany L. Langston、Vijayakumar Mavanji、Danni L. Harris、Catherine M. Kotz、Yanan Zhang

  DOI：10.1021/acs.jmedchem.1c00841

  日期：2021.6.24

  Loss of orexin-producing neurons results in narcolepsy with cataplexy, and orexin agonists have been shown to increase wakefulness and alleviate narcolepsy symptoms in animal models. Several OX2R agonists have been reported but with little or no activity at OX1R. We conducted structure–activity relationship studies on the OX2R agonist YNT-185 (2) and discovered dual agonists such as RTOXA-43 (40) with

  产生食欲素的神经元的丧失会导致发作性睡病并猝倒，而食欲素激动剂已被证明可以在动物模型中提高清醒度并减轻发作性睡病症状。已报道了几种 OX2R 激动剂，但对 OX1R 的活性很少或没有。我们对 OX2R 激动剂 YNT-185 ( 2 ) 进行了结构-活性关系研究，发现了双重激动剂，例如 RTOXA-43 ( 40 )，对 OX2R 和 OX1R 的 EC 50均为 24 nM。基于激动剂结合的 OX2R 低温电子显微镜结构的计算模型研究表明， 40结合在同一结合袋中，并且40的吡啶甲基与 OX1R 的相互作用可能有助于其高 OX1R 效力。腹腔注射40可以增加 12 个月大小鼠的清醒时间，减少睡眠时间，并增加睡眠/觉醒巩固。这项工作提供了一种有前途的双重小分子激动剂，并支持食欲素激动剂的开发，作为治疗嗜睡症等食欲素缺乏症的潜在治疗方法。
• Discovery and Optimization of Piperidyl-1,2,3-Triazole Ureas as Potent, Selective, and in Vivo-Active Inhibitors of α/β-Hydrolase Domain Containing 6 (ABHD6)
  作者：Ku-Lung Hsu、Katsunori Tsuboi、Jae Won Chang、Landon R. Whitby、Anna E. Speers、Holly Pugh、Benjamin F. Cravatt

  DOI：10.1021/jm400899c

  日期：2013.11.14

  (2-substituted)-piperidyl-1,2,3-triazole urea inhibitors of ABHD6, including compounds KT182 and KT203, which show exceptional potency and selectivity in cells (<5 nM) and, at equivalent doses in mice (1 mg kg–1), act as systemic and peripherally restricted ABHD6 inhibitors, respectively. We also describe an orally bioavailable ABHD6 inhibitor, KT185, that displays excellent selectivity against other brain and liver

  含有 6 的 α/β-水解酶结构域 (ABHD6) 是一种跨膜丝氨酸水解酶，可水解内源性大麻素 2-花生四烯酸甘油 (2-AG) 以调节神经系统中某些形式的大麻素受体依赖性信号传导。ABHD6 代谢活动和功能的全谱目前尚不清楚，并且将受益于选择性的体内活性抑制剂。在这里，我们报告了一系列先进的 ABHD6 不可逆（2-取代）-哌啶基-1,2,3-三唑脲抑制剂的开发和表征，包括化合物 KT182 和 KT203，它们在细胞中显示出非凡的效力和选择性（< 5 nM) 和，在小鼠中的等效剂量 (1 mg kg –1)，分别作为全身性和外周限制性 ABHD6 抑制剂。我们还描述了一种口服生物可利用的 ABHD6 抑制剂 KT185，它在体内对其他脑和肝脏丝氨酸水解酶具有出色的选择性。因此，我们描述了几种用于 ABHD6 生物学研究的化学探针，包括脑渗透性和外周限制性抑制剂，它们应该证明在动物模型中询问
• Morpholinyl and pyrrolidinyl analogs
  申请人：GlaxoSmithKline LLC

  公开号：US07749998B2

  公开（公告）日：2010-07-06

  The present invention relates to morpholinyl, and pyrrolidinyl analogs, pharmaceutical compositions containing them, and their use as antagonists of urotensin II.

  本发明涉及吗啡啶基和吡咯烷基类似物，含有它们的制药组合物，以及它们作为尿加压素II拮抗剂的用途。
• Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
  申请人：Malamas Michael S.

  公开号：US20090143361A1

  公开（公告）日：2009-06-04

  The invention relates to pyrido[3,2-e]pyrazines, to processes for preparing them, to pharmaceutical compositions which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 10, as active compounds for treating central nervous system disorders, obesity, and metabolic disorders.

  本发明涉及吡啶并[3,2-e]吡嗪、其制备方法、包含这些化合物的制药组合物以及这些化合物的药物用途，它们是磷酸二酯酶10的抑制剂，作为治疗中枢神经系统疾病、肥胖症和代谢紊乱的活性化合物。